Intravenous Solutions Market Expected to Reach $26.56 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Intravenous Solutions Market," The global intravenous solutions market size was valued at $11,857.7 million in 2021, and is projected to reach $26,558.4 million by 2031, registering a CAGR of 8.3% from 2022 to 2031.

Intravenous solutions restore fluid to the intravascular compartment, and some intravascular fluids are also used to facilitate the movement of fluid between compartments due to osmosis. These fluids may be isotonic, hypertonic, and hypotonic. Isotonic solutions are fluids that have a similar concentration of dissolved particles as blood. An example of an isotonic solution is 0.9% Normal Saline (0.9% NaCl). The fluid stays in the intravascular space and osmosis does not cause fluid movement between compartments as the concentration of the IV fluid is similar to the blood. The hypotonic solutions have a lower concentration of dissolved solutes than blood. An example of a hypotonic IV solution is 0.45% Normal Saline. Hypertonic solutions have a higher concentration of dissolved particles than blood. An example of hypertonic IV solution is 3% Normal Saline (3% NaCl).

The intravenous solutions market size is gaining prominence in recent years, owing to increase in the prevalence of malnutrition, the faster response time and higher efficacy associated with intravenous solution therapy and surge in the geriatric population. Further, increase in prevalence of cancer and rise in natality rate majorly supplement growth of in the global intravenous solutions market. Alternatively, lack of experienced healthcare professionals and complications of intravenous administration therapy are key factors are expected to hamper the intravenous solutions market share.

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The situation of COVID-19 has varied outcome when related to vaccinations. There is an emerging gap in the economic recovery between high-income and low and middle income countries. After the pandemic severely disrupted global trade, the world is witnessing a robust rebound, which is helping with the recovery in the year 2021. Trade contributes to speeding up economic recovery from the pandemic by providing sustained foreign demand for exports and ensuring the availability of imported intermediate products and services. The COVID-19 pandemic affected the intravenous solutions industry in a fairly positive way. According to the guidelines by American Society for Parenteral and Enteral Nutrition (ASPEN), in 2020, the early parenteral nutrition should be initiated as soon as possible in the high-risk patient for whom early gastric enteral nutrition is not feasible. It will bring down the concerns for ischemic bowel and also reduce the droplet aerosol transmission to healthcare providers by avoiding procedures involved in the initial placement and maintenance of an enteral access device. Moreover, the delivery of nutritional therapy to the patient with COVID-19 disease should follow the basic principles of critical care nutrition as recommended by European and North American societal guidelines in 2020.

Overall, the COVID-19 pandemic had a fairly positive impact on the intravenous solutions industry owing to the increased research and developments activities about the role of intravenous solutions in the COVID-19 pandemic. Moreover, increase in prevalence of some metabolic diseases also boosted the market growth amidst the pandemic situation.

By type, total parenteral nutrition segment is anticipated to grow with the largest share during the forecast period. This is attributed to the intravenous solutions market trends like increase in the use of total parenteral nutrition. On the other side, the partial parenteral nutrition segment is projected to exhibit the fastest market growth during the forecast period due to new product launches and increase in the demand of its products.

By composition, single dose amino acids segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period due to increase in number of patients of cancer. In addition, adoption of unhealthy lifestyle, increasing geriatric population, and increasing governmental initiatives also contributed toward the growth of the market. On the other side vitamins and minerals segment is projected to exhibit the fastest market growth during the forecast period, owing to increase in geriatric population, increase in technological advancements, and rise in efficacy and advantages of vitamins and mineral preparations.

By end user, hospitals and clinics segment was the major revenue contributor in 2021, and is anticipated to continue this trend during the forecast period due to increase in number of hospitals and clinics and increase in the prevalence of metabolic problems. On the other side the home care settings segment is projected to exhibit the fastest growth during the intravenous solutions market forecast period, owing to increase in geriatric population.

North America accounted for the largest share of revenue in 2021, and is anticipated to maintain its dominance from 2022 to 2031, owing to presence of large patient population, strong presence of key players, ease of drug availability, well developed healthcare infrastructure, favorable reimbursement policies in healthcare system, higher number of research, development, & innovation activities and higher adoption of advanced therapeutics. However, Asia-Pacific is expected to grow at the highest CAGR, owing to increase in number of cancer affected population and rise in awareness related to different cancers.

KEY FINDINGS OF STUDY

• By type, the total parenteral nutrition segment accounted for major share of the intravenous solutions market in 2021 as per the intravenous solutions market analysis.
• By composition, the vitamins and minerals segment is anticipated to grow with the highest CAGR throughout the forecast period.
• By end user, hospitals and clinics segment occupied major share of the intravenous solutions market in 2021.
• By region, Asia-Pacific is anticipated to grow at the highest rate during the forecast period.